Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL449158 | 0.68 | — | — | |
| SCHEMBL30901036 | 0.56 | ALDH1A1 (0.40) | CYP2A6ALOX12 | |
| SCHEMBL142660 | 0.56 | ALDH1A1 (0.40) | CYP2A6ALOX12 | |
| Hydrochloric Acid SCHEMBL2273464 | 0.54 | ALDH1A1 (0.38) | CYP2A6ALOX12 | |
| Naphthalene SCHEMBL1331142 | 0.49 | CYP2A6 (1.00) | CYP2A6ALOX12 | |
| SCHEMBL11875421 | 0.49 | MEN1 (0.61) | CYP2A6ALOX12 | |
| Naphthalene SCHEMBL1332240 | 0.49 | CYP2A6 (1.00) | CYP2A6ALOX12 | |
| SCHEMBL58153 | 0.49 | ALOX12 (0.46) | CYP2A6ALOX12 | |
| SCHEMBL49870 | 0.49 | MEN1 (0.61) | CYP2A6ALOX12 | |
| Triphenylene SCHEMBL25597 | 0.49 | HPRT1 (0.57) | CYP2A6ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150216861-A1 | CYCLOPROPYL AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2015-08-06 | — | — | US | disclosed |
| US-9029381-B2 | Cyclopropyl amide derivatives | ASTRAZENECA AB (SE) | 2015-05-12 | — | — | US | disclosed |
| EP-2805937-A1 | Cyclopropyl amide derivatives | AstraZeneca AB (SE) | 2014-11-26 | — | — | EP | disclosed |
| EP-2253615-B1 | Cyclopropyl amide derivatives | ASTRAZENECA AB (SE) | 2014-07-09 | — | — | EP | disclosed |
| EP-2195293-B1 | CYCLOPTOPYL AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2013-10-16 | — | — | EP | disclosed |
| US-20120065193-A1 | Cyclopropyl Amide Derivatives '978 | ASTRAZENECA AB (SE) | 2012-03-15 | — | — | US | disclosed |
| US-8063215-B2 | Cyclopropyl amide derivatives | ASTRAZENECA AB (SE) | 2011-11-22 | — | — | US | disclosed |
| EP-2253615-A1 | Cyclopropyl amide derivatives | AstraZeneca AB (SE) | 2010-11-24 | — | — | EP | disclosed |
| EP-2195293-A2 | CYCLOPTOPYL AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2010-06-16 | — | — | EP | disclosed |
| WO-2010062245-A1 | SPIROCYCLOBUTYL PIPERIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | WO | disclosed |
| US-20100130477-A1 | Spirocyclobutyl Piperidine Derivatives | ASTRAZENECA AB (SE) | 2010-05-27 | — | — | US | disclosed |
| US-20090076020-A1 | Cyclopropyl Amide Derivatives 978 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| WO-2009024823-A2 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150216861-A1 | CYCLOPROPYL AMIDE DERIVATIVES | HRH4, HRH2, HRH3 | CYP2A6 1444/4885ALOX12 2039/4885 |
| US-20100130477-A1 | Spirocyclobutyl Piperidine Derivatives | HRH3, HRH4, HRH2 | CYP2A6 1456/4885ALOX12 3532/4885 |
| US-20090076020-A1 | Cyclopropyl Amide Derivatives 978 | HRH4, HRH2, HRH3 | CYP2A6 2118/4885ALOX12 2688/4885 |
| US-20120065193-A1 | Cyclopropyl Amide Derivatives '978 | HRH2, HRH4, HRH3 | CYP2A6 1248/4885ALOX12 2395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.